A new prognostic model including immune biomarkers, genomic proliferation tumor markers (<i>AURKA</i> and <i>MYBL2</i>) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.

García-Torralba, Esmeralda; Navarro Manzano, Esther; Luengo-Gil, Gines; De la Morena Barrio, Pilar; Chaves Benito, Asunción; Pérez-Ramos, Miguel; Álvarez-Abril, Beatriz; Ivars Rubio, Alejandra; García-Garre, Elisa; Ayala de la Peña, Francisco; García-Martínez, Elena

A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.

García-Torralba, Esmeralda; Navarro Manzano, Esther; Luengo-Gil, Gines; De la Morena Barrio, Pilar; Chaves Benito, Asunción; Pérez-Ramos, Miguel; Álvarez-Abril, Beatriz; Ivars Rubio, Alejandra; García-Garre, Elisa; Ayala de la Peña, Francisco; García-Martínez, Elena.

Afiliação

García-Torralba E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.
Navarro Manzano E; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.
Luengo-Gil G; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
De la Morena Barrio P; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.
Chaves Benito A; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Pérez-Ramos M; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.
Álvarez-Abril B; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.
Ivars Rubio A; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
García-Garre E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.
Ayala de la Peña F; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.
García-Martínez E; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.

Front Oncol ; 13: 1182725, 2023.

Article em En | MEDLINE | ID: mdl-37313470

Palavras-chave

Breast cancer; neoadjuvant chemotherapy; neutrophil-to-lymphocyte ratio; proliferation markers; tumor-infiltrating lymphocytes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google